Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051987 | 0.92 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9AARTP53ALDH1A1 | |
| SCHEMBL3048483 | 0.87 | ALDH1A1 (0.47) | SMN1; SMN2RAB9AARTP53ALDH1A1 | |
| SCHEMBL3046437 | 0.85 | ALDH1A1 (0.44) | SMN1; SMN2RAB9AARTP53ALDH1A1 | |
| SCHEMBL3052494 | 0.80 | ADORA2A (0.48) | TP53ALDH1A1MAPTHPGDTSHR | |
| SCHEMBL3043321 | 0.80 | ECE1 (0.47) | SMN1; SMN2RAB9AALDH1A1MAPTHPGD | |
| SCHEMBL3051821 | 0.80 | ADORA2A (0.54) | ARNPC1 | |
| SCHEMBL6858792 | 0.80 | CHRM4 (0.46) | SMN1; SMN2RAB9AALDH1A1REV1MAPT | |
| SCHEMBL3045685 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2RAB9AARTP53ALDH1A1 | |
| SCHEMBL3051990 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2RAB9AARTP53ALDH1A1 | |
| SCHEMBL6858781 | 0.78 | CHRM4 (0.46) | SMN1; SMN2TP53REV1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797878-A2 | Benzothiazole derivatives | F. Hoffmann-La Roche AG (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | claimed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | claimed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | claimed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | claimed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | claimed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | claimed |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-29 | — | — | US | disclosed |
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2008-05-08 | — | — | US | disclosed |
| EP-1303272-B1 | BENZOTHIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| US-7317007-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1797878-A2 | Benzothiazole derivatives | F. Hoffmann-La Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108809-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3173/4885RAB9A 3119/4885AR 601/4885 |
| US-20080125419-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3476/4885RAB9A 3104/4885AR 621/4885 |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3173/4885RAB9A 3119/4885AR 601/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3173/4885RAB9A 3119/4885AR 601/4885 |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3317/4885RAB9A 3351/4885AR 690/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3476/4885RAB9A 3104/4885AR 621/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3173/4885RAB9A 3119/4885AR 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.